Bayer AG (ADR)
General ticker "BAYRY" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $42.3B (TTM average)
Bayer AG (ADR) follows the US Stock Market performance with the rate: 40.1%.
Estimated limits based on current volatility of 0.9%: low 13.95$, high 14.20$
Factors to consider:
- Company pays dividends (annually): last record date 2026-04-28, amount 0.03$ (Y0.21%)
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [8.95$, 14.66$]
- 2026-12-31 to 2027-12-31 estimated range: [10.38$, 16.49$]
Financial Metrics affecting the BAYRY estimates:
- Positive: with PPE of 7.9 at the end of fiscal year the price was neutral
- Positive: 11.37 < Operating cash flow per share per price, % of 12.37
- Positive: 11.29 < Operating profit margin, % of 15.26
- Positive: Industry inventory ratio change (median), % of 0.50 <= 1.15
- Positive: 14.78 < Industry operating profit margin (median), % of 24.67
- Positive: Industry earnings per price (median), % of 6.62 > 6.58
- Positive: Interest expense per share per price, % of 4.66 <= 10.35
- Positive: 5.56 < Industry operating cash flow per share per price (median), % of 5.61
- Positive: -7.72 < Return on assets ratio (scaled to [-100,100]) of -3.05
Short-term BAYRY quotes
Long-term BAYRY plot with estimates
Financial data
| YTD | 2024-12-31 | 2025-12-31 |
|---|---|---|
| Operating Revenue | €46,606.00MM | €43,776.28MM |
| Operating Expenses | €43,279.00MM | €37,096.73MM |
| Operating Income | €3,327.00MM | €6,679.54MM |
| Non-Operating Income | €-5,661.00MM | €-9,685.05MM |
| Interest Expense | €2,358.00MM | €1,654.04MM |
| R&D Expense | €6,209.00MM | €5,541.31MM |
| Income(Loss) | €-2,334.00MM | €-3,005.51MM |
| Taxes | €212.00MM | €447.61MM |
| Net Income(Loss)* | €-2,552.00MM | €-3,477.13MM |
| Stockholders Equity | €31,908.00MM | €25,935.96MM |
| Inventory | €13,403.00MM | €12,372.73MM |
| Assets | €110,850.00MM | €110,558.93MM |
| Operating Cash Flow | €7,368.00MM | €4,390.59MM |
| Capital expenditure | €2,778.00MM | €2,388.84MM |
| Investing Cash Flow | €164.00MM | €-1,545.50MM |
| Financing Cash Flow | €-7,178.00MM | €-2,099.72MM |
| Earnings Per Share** | €-0.65 | €-0.88 |
| Ordinary share to ADR | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.